Cardarine (GW-501516)

GW-501516 (Cardarine) was developed by GlaxoSmithKline as a PPARδ agonist for metabolic syndrome, with promising early results on lipids, insulin sensitivity, and body composition — but GSK terminated the program in 2007 after long-term rodent toxicology studies showed tumor development across multiple organs. This wasn't a rumor or a competitor's citation error — it's real, and the mechanism has since been independently studied and published: GW501516 significantly enhanced colitis-associated colorectal cancer in a mouse model, increasing pro-inflammatory markers (COX-2, IL-6, IL-8) and nutrient-transporter expression that supports tumor growth. Zhou et al., Eur J Pharmacol, 2019 A second paper on PPARδ/VEGF crosstalk in cancer progression turned up in this research but couldn't be verified against the primary source (PubMed access was blocked in this pass) — not included as a citation until confirmed directly.

The honest counterpoint, stated fairly: the original GSK toxicology dosing was reportedly far higher than typical research-use doses and sustained for two years continuously — a very different exposure than a short cycle at a lower dose. No documented human cancer cases have been linked to Cardarine as of this research. But "no documented human cases" reflects an absence of long-term human safety data, not evidence of safety — this compound carries a real, mechanistically-supported cancer signal that shouldn't be minimized.

No human dosing trial with a validated safe protocol was found in this research pass — the compound's own development history (discontinued for the reason above) means there isn't a dose to point to as clinically established.

The cancer-promotion signal above is the dominant safety consideration for this compound. Given that, this page should not present Cardarine with the same "here's the benefits, here's the mild side effects" template used for lower-risk compounds — the tumor-promotion finding needs to be the lead, not a footnote.